TMCnet News
Watch our Hot Newsletter!! Sign Up Today!! KATX,ALIF,BIEL,SNBP,SXLP,SINX(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (PINKSHEETS: KATX) KAT Exploration Inc., (OTCBB: ALIF) Artificial Life, Inc., (PINKSHEETS: BIEL) BioElectronics Corp., (OTCBB: SNBP) Sinobiopharma, Inc., (OTCBB: SXLP) Signature Exploration and Production Corp., (OTCBB: SINX) Sionix Corp. www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! [email protected] or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: KATX - KAT Exploration Inc.) LATEST NEWS!! KAT Exploration Retires Additional 300 Million Shares, Engages New Consulting Group, Dual Listing and Carbon Credit Assets on the Horizon MOUNT PEARL, NL, Jan 19, 2010 -- KAT Exploration Inc. (PINKSHEETS: KATX) www.KATexploration.com, along with its private group of investors who recently funded the company with up to $5 million for 50,000,000 restricted shares, has made the decision to retire and eliminate an additional 300,000,000 shares from its treasury of authorized shares of which the new amount of authorized shares will be 730,000,000 shares. Both the company and the group of private investors believe that this reduction will further enhance and solidify shareholder confidence with its secondary directions. KAT Exploration has secured Private Independent Consultants for 5 years that will rapidly provide an array of major mining support and other ventures to be announced later that will significantly enhance shareholder value. The Private Independent Consultants possess a wealth of experience in the business arena throughout the world and will bring an entire new level of professionalism and key relationships to KAT Exploration as it moves forward. We feel it to be in the best interest of our shareholders for KAT to seek a dual listing on a major exchange. Along with a US listing, we will now proceed to meet the requirements of gaining a listing on one of the largest Asian Stock Market Exchanges, later to be named. This too is being organized by our Private Independent Consultants. Along with the new listing, our Consultants will assist in increasing shareholder value by diversifying and adding "Carbon Credit" projects into KAT's portfolio of assets. It is expected that these projects will generate significant amounts of revenue to KAT's bottom line financials. A choice of Carbon Credit projects in Brazil and Sierra Leone are being considered at this time. KAT believes that adding a piece of carbon credit assets to its portfolio will greatly enhance shareholder value. The New York Times released an article that explained how carbon trading is one of the "fastest-growing specialties in financial services" and how many companies are trying to figure out how to get "a slice of a market now worth about $30 billion and that could grow to $1 trillion within a decade." The article further states that "Carbon will be the world's biggest commodity market, and it could become the world's biggest market over all." The World Bank manages over $2 billion dollars to purchase credits of greenhouse gas emission reductions from projects that are expected to be registered for the purposes of the Kyoto Protocol's Article 12 (Clean Development Mechanism) or Article 6 (Joint Implementation). As governed by the United Nations Framework Convention on Climate Change (UNFCCC), the Kyoto Protocol is an international agreement linked to the UNFCCC. The major feature of the Kyoto Protocol is that it sets binding targets for 37 industrialized countries and the European community for reducing greenhouse gas (GHG) emissions. Private consulting arrangements have been agreed upon which the company believes will greatly contribute towards the growth of the company to justify any current increase in its share structure to provide this array of mining and listing support while securing carbon credit assets. All of these actions are believed to greatly enhance shareholder value of which will be announced later. This is expected to be the last change in capital structure to complete the portfolio of growth and ventures the company will be pursuing, barring any major joint ventures that may be pursued. The company's final share structure will be updated on pinksheets.com very soon. We would like to emphasize that while our Consultants will be concentrating on new projects, our mineral properties, especially Gold, will remain the center of our focus. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: ALIF - Artificial Life, Inc.) LATEST NEWS!! Artificial Life Launches Groundbreaking New M-Commerce Platform: OPUS-M LOS ANGELES and HONG KONG, Jan 21, 2010 -- Artificial Life, Inc., (OTCBB: ALIF), , today announced their new OPUS-M(TM) product, one of the most comprehensive m-commerce platforms to be released into the mobile market. OPUS-M is a modular, carrier-grade m-commerce platform for business customers, content providers, and end-consumers. Artificial Life has worked for several years on the development and distribution of cutting-edge mobile games and applications for many mobile operating systems and platforms, having developed a vast catalogue of proprietary tools, technology, and mobile products. OPUS-M is a culmination of Artificial Life's experience, expertise, and insight regarding customers' needs for an m-commerce platform that will drive sales and facilitate mobile integration. Some of Artificial Life's previous mobile products, such as the MobileBooster and the powerful Smart Engine (SEMP) technology, and various core mobile modules to support carriers and operators, have been expanded upon, integrated and brought together to create the new powerful OPUS-M mobile commerce platform. OPUS-M's architecture enforces a modular and very flexible format made up of client selectable components catered to the specific needs of each customer, whether that be increased security, massive transaction support, fancy mobile features or enhanced application browsing. OPUS-M's components are separated into the 3 layers outlined below: the Core, the Service Layer, and the Application Layer. Core The Core of OPUS-M provides a framework upon which modules and applications are built. The core is part of OPUS-M for all clients. Some of the more notable components belonging to the core include the following: -- Messaging Framework -- Security -- Device Recognition -- Image Re-sampling -- Transaction History -- Billing Service Layer The Service Layer of OPUS-M addresses and offers several selectable components to cater to the business needs of customers setting up their m-commerce storefronts with such components as: -- Sales and Marketing Support -- Customer Relationship Management -- Content Management -- Business Intelligence and Reports -- Augmented Reality and New Media apps -- Location-based Systems -- Application Migration -- Interface Adapter for 3rd Party Tools and Apps Application Layer The Application Layer of OPUS-M is comprised of Artificial Life business modules as well as 3rd party contributions to the platform. By launching applications on the OPUS-M platform, content providers may leverage the existing customer base and exposure provided by service operators. -- Business Applications -- Games -- New Media -- Social Networking With so much to offer, OPUS-M appeals to a wide customer base in the mobile market: business customers, content providers, and end-consumers. Clients can select their individual set of modules needed, providing support for social networking and even the latest augmented reality technology. The pricing of the components is based on a monthly rental and usage fee and can be adjusted according to the transaction numbers executed via the platform. Artificial Life also provides hosting services for the platform and applications and cloud computing and data distribution support for its clients. OPUS-M is scheduled for commercial release in Q2, 2010. "As recently announced, we will focus in 2010 on products and services for the business community in addition to our mobile games and applications. OPUS-M, with its broad appeal, flexible module concept, innovative pricing, hosting support and comprehensive feature set is our key product to implement the new expanded business strategy. Further details about OPUS-M will be provided on our corporate website soon," said Eberhard Schoneburg, CEO of Artificial Life, Inc. About Artificial Life, Inc. Artificial Life, Inc. (OTCBB: ALIF) is a public U.S. corporation headquartered in Los Angeles, with its production center in Hong Kong and additional offices in Berlin (EMEA headquarter) and Tokyo. As a leading, full-service provider of mobile broadband 3G technology, mobile participation TV, mobile gaming, and content and business applications, Artificial Life provides 2D and 3D multi- and single- player rich-media applications for 3G, 3.5G and 4G network-enabled mobile phones. Recognized internationally for outstanding content quality and technology, Artificial Life transcends traditional modes of mobile communications and interactive gaming. For more information, please visit http://www.artificial-life.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: BIEL - BioElectronics Corp.) LATEST NEWS!! BioElectronics Files Application with FDA for Reclassification -- Company to File PMA Application FREDERICK, Md., Jan 19, 2010 -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it filed an application with the U.S. Food and Drug Administration (FDA) for reclassification to Class II of its existing device which was given FDA Class III approval in 2002. Additionally, based on information provided during a recent meeting with FDA personnel, the Company will also be filing an application for Pre-Marketing Approval (PMA). Reclassification will help facilitate over-the-counter (OTC) clearance in United States of its ActiPatch(R) and Allay(TM) products. BioElectronics products are currently cleared for sale in dozens of countries including Canada, China, Japan, Korea and Australia. BioElectronics devices also have the CE Mark (European Common Market) certification for OTC sales and have been approved by Health Canada. BioElectronics' devices are currently considered thermal pulsed electromagnetic field (PEMF) therapy devices, but additional evidence shows the devices do not produce heat and should be classified as non-thermal devices. "We have assembled a substantial amount of compelling documentation to present to FDA that outlines not only the extreme safety of our products, but also the high level of efficacy," said Andrew Whelan, CEO of BioElectronics. "Our products have been used by hundreds of thousands of individuals worldwide without a single safety complaint. The vast majority of these users had enjoyed substantial pain relief and decreased recovery intervals after injury or surgery. Thousands of others have received pain relief and accelerated healing of chronic musculoskeletal complaints. We have also completed and have several ongoing Institutional Review Board (IRB) supervised clinical studies sponsored by prominent physicians, which has clearly demonstrated the high efficacy of our products. We believe the examiners at FDA will be impressed by the compelling case we will present to them seeking reclassification. We strongly believe our products are Class II devices, which should receive OTC clearance in order to help the millions of American pain sufferers who are seeking pain relief and alternatives to potentially dangerous OTC drugs such as acetaminophen and ibuprofen." Based on information provided to the Company by FDA personnel, BioElectronics has decided to also file a Pre-Market Approval (PMA) application. "We believe there are significant benefits to our Company and its shareholders to have our devices cleared via the PMA process as it effectively allows us to define a completely new space within the medical device and pain management markets," Whelan said. "Clearance under PMA will also allow us to better control our trade secrets and would prevent any would-be competitor from using our device as a predicate in order to receive clearance, ultimately making it much more difficult for anyone to compete with us in the domestic market place. We plan to immediately begin the PMA clearance process while our other applications run in parallel." BioElectronics previously filed for premarketing clearance for ActiPatch and Allay. That filing, which is separate from both the reclassification and the upcoming PMA application, is still pending. The Company's technology is currently categorized by FDA as a Class III device which is the most stringent regulatory category for devices. According to the FDA, Class III devices are those for which insufficient information exists to ensure the safety and effectiveness solely through general or specific controls. Class III devices are usually those that support or sustain human life, are of substantial importance to preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. Class II devices, are those for which general controls alone are insufficient to assure safety and effectiveness, and existing methods are available to provide such assurances. In addition to complying with general controls, Class II devices may be subject to special controls. These special controls may include special labeling requirements, mandatory performance standards and post-market surveillance. BioElectronics maintains its proposed labeling more than adequately meets these requirements for special controls enabling consumers to both safely and effectively realize the benefits of ActiPatch and Allay. "While international marketing efforts are expanding at a very rapid pace, with major Direct TV commercial initiatives currently being launched in Canada, Western Europe, Turkey, Latin America, and China, in addition to other areas, domestic clearance to market our products remains an important objective for BioElectronics," Whelan said. About BioElectronics Corporation BioElectronics Corporation is the maker of ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: SNBP - Sinobiopharma, Inc.) LATEST NEWS!! Sinobiopharma Announces Second Quarter 2010 Financial Results Revenue Increases to Approximately $2.1 Million; Net Income Increases to Approximately $1.1 Million NANTONG CITY, China, Jan 19, 2010 -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP, "Sinobiopharma" or the "Company"), a fully integrated and highly innovative biopharmaceutical company engaged in the research and development, manufacture and marketing of pharmaceutical products in China, today announced financial results for the second quarter ended November 30, 2009. "We achieved excellent revenue and net income growth in the second quarter," said Dr. Lequn Huang, Sinobiopharma's Chairman and CEO stated. "The strong growth is largely due to our increased marketing efforts and strong demand for our main product KuTai (cisatracurium besylate). KuTai is replacing older-generation muscle relaxants since it is uniquely differentiated by both its performance profile and its convenience. KuTai is the only muscle relaxant that can be stored at room temperature. We feel confident that KuTai will continue to gain market share." Business Outlook Dr. Huang expects strong results to continue with the launch of Sinobiopharma's newest drug YiTai (perindopril), which has obtained all approvals for production. The Company believes that YiTai will be launched as a first-to-market drug and therefore will enjoy marketing exclusivity and a price premium. There has been strong demand for YiTai to date, and strong sales will help to diversify the revenue stream from Sinobiopharma's product portfolio. About Sinobiopharma Sinobiopharma Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: SXLP - Signature Exploration and Production Corp.) LATEST NEWS!! ignature Exploration and Production Releases Reserve Report on Koliba Total Reserve Value is Estimated to Be in Excess of $38 Million HOUSTON, Jan 20, 2010 -- Signature Exploration and Production Corporation (OTCBB: SXLP) today released a synopsis of the 'Reserve Report' that was recently prepared by project operator Carter E&P, LLC. According to Carter E&P, LLC, the Koliba Prospect's value is estimated at $38,898,000 and Signature Exploration's 15% interest is valued in excess of $5,834,000. These figures are based on $77.28 Bbls of oil and $5.59 Mcf of gas. The operator is on schedule to commence drilling in approximately 30 days. Steve Weldon, Chairman and CEO of Signature Exploration and Production Corp., stated, "This initial information, when combined with current oil and natural gas market conditions, represents what we anticipate to be a well with stable, predictable cash flows and good returns on investment." About the Koliba Prospect: The Koliba Prospect is a 173-acre lease located in the highly productive North McFadden Field near Bloomington, Texas. The Company has identified 3 target zones at 5,880', 5,350', and 4,930', in the Frio Sands. The Koliba Prospect will be drilled 250 feet from an originally large producing well and is considered a low risk / high reward prospect due to its proximity to previous wells in the prolific Frio interval. Signature Exploration and Production Corp. Signature Exploration and Production Corp. is an independent energy company engaged in the exploration, development, exploitation and acquisition of on-shore oil and natural gas properties in conventional producing areas along the gulf coast of Texas. Management's strategy is to continue making acquisitions of select properties that have been identified as economically attractive, technically and geologically sound and have significant upside potential. Visit www.signatureexploration.com for more information. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: SINX - Sionix Corp.) LATEST NEWS!! Sionix Corporation Announces Letter from Chief Executive Officer SANTA MONICA, Calif., Jan 20, 2010 -- Sionix Corporation (OTCBB:SINX), a Santa Monica, CA-based designer and manufacturer of "Safe Water Systems" for commercial, industrial, and public water treatment applications, today announced the release of a letter to the shareholders from Jim Currier, its Chief Executive Officer. A copy of the letter is available here. About Sionix Based in Santa Monica, Calif., Sionix designs innovative and advanced "Safe Water Systems" intended for use in defense, government facilities, emergency water supplies during natural disasters, hospitals, pharmaceuticals, resorts and hotels, housing development projects, industrial process waters including food, dairy and meat processing, and brackish waste water from oil and gas drilling. Intended applications also include desalinization and pre-treatment for reverse osmosis and other membrane applications, as well as industrial wastewater, bottled water, industrial process water, food, dairy, agribusiness, meat processing, and hog and poultry operations. ------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. ((Comments on this story may be sent to [email protected])) (c) 2010 M2 COMMUNICATIONS |